Federal Register / Vol. 75, No. 180 / Friday, September 17, 2010 / Notices 57039 

Type of respondent Number of 

respondents 

Frequency of 

response 

Average time 

per response 

Annual hour 

burden 

Totals ...................................................................................................... 1,500 ........................ .......................... 701 

* These individuals are included in the 1,500 above. 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

For Further Information Contact: To 

request more information on the 

proposed project or obtain a copy of the 

data collection plans and instruments, 

contact Dr. Luigi Ferrucci, Principal 

Investigator, NIA Clinical Research 

Branch, Harbor Hospital, 5th Floor, 

3001 S. Hanover, Baltimore, MD 21225, 

or call this non-toll-free number (410) 

350–3936 or E-mail your request 

including your address to: 

Ferruccilu@grc.nia.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication. 

Dated: September 8, 2010. 

Melissa Fraczkowski, 

Project Clearance Liason, NIA, National 

Institutes of health. 

[FR Doc. 2010–23263 Filed 9–16–10; 8:45 am] 

BILLING CODE 4140–01–P 

FEDERAL TRADE COMMISSION 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–1356–N] 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Inspector General 

Medicare Program; Workshop 

Regarding Accountable Care 

Organizations, and Implications 

Regarding Antitrust, Physician SelfReferral, Anti-Kickback, and Civil 

Monetary Penalty (CMP) Laws 

AGENCY: Federal Trade Commission 

(FTC), Centers for Medicare & Medicaid 

Services (CMS), and Office of the 

Inspector General (OIG), HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces a 

public workshop hosted by the Federal 

Trade Commission (FTC), the Centers 

for Medicare & Medicaid Services 

(CMS), and the Office of the Inspector 

General (OIG) of the Department of 

Health and Human Services (DHHS). 

This workshop will include panel 

discussions and a listening session on 

certain legal issues related to 

Accountable Care Organizations (ACOs). 

Physicians, physician associations, 

hospitals, health systems, consumers, 

and all others interested in ACOs are 

invited to participate, in person or by 

calling into the teleconference. The 

meeting is open to the public, but 

attendance is limited to space and 

teleconference lines available. An 

agenda will be posted on the CMS Web 

site at http://www.cms.gov/center/ 

physician.asp prior to the session. 

DATES: Meeting Date: The public 

workshop will be held on Tuesday, 

October 5, 2010 from 9 a.m. until 4:30 

p.m. Eastern Daylight Time (E.D.T.). 

Deadline for Meeting Registration and 

Request for Special Accommodations: 

Registration opens on September 16, 

2010. Registration must be completed by 

5 p.m. e.d.t. on September 27, 2010. 

Requests for special accommodations 

must be received by 5 p.m. e.d.t. on 

September 27, 2010. 

Deadline for Submission of Written 

Comments or Statements for Discussion 

at the Workshop: Written comments or 

statements to be considered for 

discussion at the Workshop may be sent 

via mail or electronically to the address 

specified in the ADDRESSES section of 

this notice and must be received by 5 

p.m. E.D.T. on September 27, 2010. 

ADDRESSES: Meeting Location: The 

public workshop will be held in the 

main auditorium of the Central Building 

of the Centers for Medicare & Medicaid 

Services, 7500 Security Boulevard, 

Baltimore, MD 21244–1850. 

Registration and Special 

Accommodations: Persons interested in 

attending the meeting in person must 

register by completing the on-line 

registration via the CMS Web site at 

http://www.cms.hhs.gov/apps/events/ 

event.asp?id=607 Individuals who 

require special accommodations should 

send an e-mail request to 

thomas.carey@hhs.gov or via regular 

mail to the address specified in the FOR

FURTHER INFORMATION CONTACT section of 

this notice. Information regarding 

attending via teleconference and Web 

conference will be posted on the CMS 

Web site at http://www.cms.gov/center/ 

physician.asp prior to the session. 

Written Comments or Statements: 

Written comments or statements may be 

sent via e-mail to 

ACOlegalissues@cms.hhs.gov or sent via 

regular mail to: Attn: ACO Legal Issues, 

Mail Stop C5–15–12, Centers for 

Medicare & Medicaid Services, 7500 

Security Boulevard, Baltimore, MD 

21244–1850. 

All persons planning to make a 

statement in person at the afternoon 

listening session are urged to submit 

statements in writing in advance of the 

listening session and should 

subsequently submit the information 

electronically by the timeframe 

specified in the DATES section of this 

notice. 

FOR FURTHER INFORMATION CONTACT: 

Kristin Bohl at (410) 786–8680, for 

issues specific to CMS. 

Elizabeth Jex at (202) 326–3273, for 

issues specific to FTC. 

Patrice Drew at (202) 619–1368, for 

issues specific to OIG. 

Thomas Carey at (410) 786–4560, for 

general and logistical issues. You may 

also send general and logistical 

inquiries about this workshop via eVerDate Mar<15>2010 14:46 Sep 16, 2010 Jkt 220001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\17SEN1.SGM 17SEN1

wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
57040 Federal Register / Vol. 75, No. 180 / Friday, September 17, 2010 / Notices 

1Stephen M. Shortell, Lawrence P. Casalino, 

Elliott Fisher, ‘‘Implementing Accountable Care 

Organizations,’’ Policy Brief (May 2010), available 

at: http://www.law.berkeley.edu/files/chefs/ 

Implementing_ACOs_May_2010.pdf. 

mail to thomas.carey@hhs.gov or via 

regular mail at Centers for Medicare & 

Medicaid Services, Mail Stop C5–15– 

12, 7500 Security Boulevard, 

Baltimore, MD 21244–1850. 

SUPPLEMENTARY INFORMATION: 

I. Background 

The Affordable Care Act seeks to 

improve the quality of health care 

services and to lower health care costs 

by encouraging providers to create 

integrated health care delivery systems. 

These integrated systems will test new 

reimbursement methods intended to 

incentivize providers to enhance health 

care quality and lower costs. One 

important delivery system reform is the 

Affordable Care Act’s Shared Savings 

Program, section 3022 of the Affordable 

Care Act, which promotes the formation 

and operation of Accountable Care 

Organizations (ACOs). Under this 

provision, ‘‘groups of providers . . . 

meeting the criteria specified by the 

Secretary may work together to manage 

and coordinate care for Medicare . . . 

beneficiaries through an [ACO].’’ An 

ACO may receive payments for shared 

savings if the ACO meets certain quality 

performance standards established by 

the Secretary. In addition, under section 

3021 of the Affordable Care Act, the 

Secretary is authorized to test whether 

ACOs improve the quality of care for 

Medicare beneficiaries and reduce 

unnecessary costs for the Medicare 

program. 

A variety of legal regimes—such as 

the antitrust laws, the physician selfreferral prohibition (section 1877 of the 

Social Security Act (the Act)), the 

Federal anti-kickback statute (section 

1128B(b) of the Act), and the civil 

monetary penalty (CMP) law (sections 

1128A(b)(1) and (2) of the Act)—will 

apply to ACOs, including those 

participating in the Medicare Shared 

Savings Program pursuant to section 

3022 of the Affordable Care Act. The 

Federal Trade Commission (FTC) 

together with the Department of Justice 

Antitrust Division enforce the Federal 

antitrust laws; the Centers for Medicare 

& Medicaid Services (CMS) has primary 

enforcement authority for the physician 

self-referral prohibition; and the Office 

of the Inspector General (OIG) of the 

Department of Health and Human 

Services (DHHS) enforces the antikickback statute and CMP law and 

imposes CMPs for knowing violations of 

the physician self-referral prohibition. 

Each of these agencies recognizes the 

importance of evaluating how to apply 

these laws to the creation and operation 

of ACOs. All of these laws also are 

relevant to the regulations that CMS is 

developing to implement the Medicare 

Shared Savings Program. 

In addition, an ACO may wish to 

contract with payers in the private 

health care market, as well as with CMS. 

Experience has shown that integrating 

health care delivery among independent 

providers is a complex process that 

requires a substantial commitment of 

health care providers’ resources and 

time.1 Recent commentary suggests that, 

because of the resources and time 

required to integrate independent 

provider practices, health care providers 

are more likely to integrate their care 

delivery for Medicare and Medicaid 

beneficiaries if they also use the same 

delivery system for patients covered by 

health care insurance in the private 

market. The potential for ACOs to 

operate in both public and private 

insurance markets further supports the 

need to explore the application to ACOs 

of the laws discussed above for which 

the FTC, CMS, and OIG have 

enforcement responsibilities. 

II. Workshop Format, Discussion 

Topics, and Solicitation of Public 

Comment 

A. Format of Panel Discussions and 

Listening Session 

To explore these issues, the FTC, 

CMS, and OIG will be hosting a public 

workshop on October 5, 2010 to obtain 

information from industry stakeholders 

who have an interest in, or experience 

with, the development and operation of 

ACOs. One key focus of the workshop 

will be to assess how the variety of 

possible ACO structures in different 

health care markets could affect the 

prices and the quality of health care 

delivered to privately insured 

consumers, as well as to Medicare and 

Medicaid beneficiaries. Another key 

focus will be whether and, if so, how 

the requirements of the laws discussed 

above could or should be addressed in 

the regulations that CMS is developing 

for the Medicare Shared Savings 

Program. Finally, the workshop will 

focus on whether and, if so, to what 

extent any safe harbors, exceptions, 

exemptions, or waivers from the laws 

discussed above may be warranted. 

1. FTC Panel Discussions 

The two morning sessions will be 

devoted to exploring antitrust issues 

through moderated panel discussions. 

Panelists for both antitrust panels will 

include health care providers with 

integration efforts planned and 

underway, payers (insurers, employers, 

and consumers), and experts in health 

care policy. 

At the first session, the panelists will 

address circumstances under which 

collaboration among independent health 

care providers in an ACO (not including 

a merger), permits ACO providers to 

engage in joint price negotiations with 

private payers without running the risk 

of engaging in illegal price fixing under 

the antitrust laws. In particular, the 

panel will address the indicia of clinical 

integration sufficient to indicate that an 

ACO is likely to enable participating 

providers to improve the quality of their 

health care services and whether joint 

price negotiation is reasonably 

necessary to achieve these efficiencies. 

Such indicia could include, for 

example, the degree to which the 

providers engage in integrated activities, 

the information processes used to 

ensure that providers are coordinating 

patient care, incentives for providers to 

adhere to evidence-based care protocols 

such as financial risk sharing, and/or 

financial and resource investments 

made by providers. The panel also will 

address options for dealing with 

Medicare ACOs that fail to achieve 

CMS-required quality performance 

standards and that, therefore, might no 

longer be eligible for Medicare Shared 

Savings Program payments under 

section 3022 of the Affordable Care Act. 

At the second morning session, the 

panelists will explore ways to encourage 

formation of multiple ACOs among 

otherwise independent providers so that 

competition among ACOs in any given 

geographic market will drive improved 

quality and affordability of health care. 

For example panelists will explore: (1) 

The analysis of arrangements where 

providers or facilities are exclusive, or 

non-exclusive, to an ACO; (2) the 

impact, if any, of risk-based contracting 

(for example, global payments and/or 

capitated rates) on market power 

assessments; (3) ways to assess whether 

formation of an ACO among 

independent providers may allow the 

ACO to increase price and reduce the 

quality of care; and (4) the financial, 

utilization, outcome, and patient 

experience data necessary to monitor 

and measure the impact of an ACO on 

prices and quality in the relevant 

markets. 

2. CMS and OIG Panel Discussion and 

Listening Session 

The afternoon will consist of two 

separate sessions regarding how ACOs 

will interact with the physician selfreferral prohibition, the anti-kickback 

statute, and the CMP law in order to 


wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
Federal Register / Vol. 75, No. 180 / Friday, September 17, 2010 / Notices 57041 

better inform CMS and OIG (HHS 

Agencies) decision-making regarding 

the application of these laws to ACOs. 

The first session will be a moderated 

panel discussion of industry 

stakeholders, including representatives 

of providers, suppliers, and health 

policy experts who will focus on the 

discussion topics listed below. 

During the second session, a listening 

session, there will be an opportunity for 

other attendees to provide brief 

comments on the same topics either in 

person or via the teleconference, as time 

permits. An agenda for the moderated 

panel discussions and the listening 

session will be released at a later time. 

B. Discussion Topics and Solicitation of 

Public Comment 

The FTC and the HHS Agencies are 

interested in comments addressing the 

intersection of these laws and the 

various business models envisioned for 

ACOs with both the antitrust laws and 

the fraud and abuse laws. The FTC and 

the HHS Agencies are interested in 

details from the public concerning the 

types of contractual and financial 

relationships under existing or planned 

ACOs that might trigger or implicate the 

antitrust laws, the physician self-referral 

prohibition and/or the anti-kickback 

statute (for example, compensation and 

ownership relationships), as well as 

payment arrangements that might 

implicate the CMP law (for example, 

gainsharing structures). In addition to 

obtaining information on the planned 

legal structures or business models of 

ACOs, the HHS Agencies seek 

comments addressing whether the 

public believes that the incentive 

payments or shared savings to ACOs, or 

the distribution of these payments to the 

physicians or other providers and 

suppliers in the ACO, would trigger or 

implicate the physician self-referral 

prohibition, the anti-kickback statute, 

and/or the CMP law. Much of the 

discussion to date has involved the 

integration of group practices, hospitals, 

and networks of physicians or other 

professionals into ACOs, and we are 

interested in how these types of 

arrangements might be constrained by 

these laws. We are asking the public to 

describe in detail any potential 

impediments, including an explanation 

as to how current physician self-referral 

prohibition exceptions or anti-kickback 

statute safe harbors might be inadequate 

to address the types of financial 

arrangements that will be created by 

ACOs. We are also interested in 

explanations about the extent to which 

these laws currently accommodate 

integration and ways in which existing 

exceptions and safe harbors might be 

tailored to further address integration. 

1. Exercise of the Section 3022 

Affordable Care Act Waiver Authority 

Section 3022 of the Affordable Care 

Act gives the Secretary authority to 

waive such requirements of Title XVIII 

as well as sections 1128A and 1128B of 

the Act as may be necessary to carry out 

the provisions of section 3022 of the 

Affordable Care Act. The HHS Agencies 

are interested in hearing from the public 

whether a waiver, to the extent granted, 

should apply only to the incentive 

payments distributed to the ACOs and 

participating physicians (and other 

participating suppliers or ACO 

professionals), or whether it would be 

necessary to create a broader waiver that 

would also apply to other financial 

relationships created by ACOs that 

participate in the Medicare Shared 

Savings Program under section 3022 of 

the Affordable Care Act. If the public 

believes that a broader waiver is 

necessary, the HHS Agencies request 

that interested stakeholders provide 

support for this view. For example, if 

the public recommends a waiver that 

applies to all contractual service 

relationships between ACOs and ACO 

professionals, the HHS Agencies are 

interested to hear why this is necessary 

and what safeguards should be required 

as part of such a broad waiver. 

2. Creation of New Stark Exception and 

Anti-Kickback Safe Harbor 

An alternative to the use of the 

Secretary’s waiver authority under 

section 3022 of the Affordable Care Act 

would be for the Secretary to use her 

authority under section 1877(b)(4) of the 

Act to create a new shared savings/ 

incentive payment exception to the 

physician self-referral prohibition. 

Similarly, OIG could consider a new 

safe harbor under section 1128B(b)(3) of 

the Act. CMS has attempted to address 

this issue in prior proposed rulemaking 

under section 1877 of the Act, and the 

HHS Agencies are interested in the 

public’s recommendations for how a 

meaningful exception and safe harbor 

for the incentive payments related to the 

newly created ACOs could be crafted. In 

particular, they are interested in how a 

physician self-referral exception could 

be designed given that any new 

exception under section 1877 of the Act 

must present no risk of program or 

patient abuse. 

C. Content and Timeframe for 

Submission of Written Comments or 

Statements 

Written comments or statements 

should not include any sensitive 

personal information, such as an 

individual’s Social Security number; 

date of birth; driver’s license number or 

other State identification number or 

foreign country equivalent; passport 

number; financial account number; or 

credit or debit card number. Comments 

also should not include any sensitive 

health information, such as medical 

records and other individually 

identifiable health information. 

Written comments or statements will 

be accepted and considered for 

discussion at the meeting if they are 

received at the address specified in the 

ADDRESSES section of this notice by the 

date specified in the DATES section of 

this notice. 

III. Registration Instructions 

For security reasons, any persons 

wishing to attend this meeting must 

register by the date listed in the DATES

section of this notice. Persons interested 

in attending the meeting in person must 

register by completing the on-line 

registration via the designated Web site 

at http://www.cms.hhs.gov/apps/events/ 

event.asp?id=607. The on-line 

registration system will generate a 

confirmation page to indicate the 

completion of your registration. Please 

print this page as your registration 

receipt. 

Individuals may also participate in 

the listening session by teleconference 

or webcast. Information regarding 

attending via teleconference and Web 

conference will be posted on the CMS 

Web site at http://www.cms.gov/center/ 

physician.asp prior to the session. 

An audio download and transcript of 

the listening session will be available 2 

weeks after completion of the listening 

session through the CMS Web site 

Physician Center Spotlights at http:// 

www.cms.gov/center/physician.asp. 

IV. Security, Building, and Parking 

Guidelines 

This meeting will be held in a Federal 

government building; therefore, Federal 

security measures are applicable. In 

planning your arrival time, we 

recommend allowing additional time to 

clear security. The on-site check-in for 

visitors will begin at 7:30 a.m. E.D.T. 

Please allow sufficient time to complete 

security checkpoints. 

Security measures include the 

following: 

• Presentation of government-issued 

photographic identification to the 

Federal Protective Service or Guard 

Service personnel. 

• Interior and exterior inspection of 

vehicles (this includes engine and trunk 

inspection) at the entrance to the 

grounds. Parking permits and 


wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1
57042 Federal Register / Vol. 75, No. 180 / Friday, September 17, 2010 / Notices 

instructions will be issued after the 

vehicle inspection. 

• Passing through a metal detector 

and inspection of items brought into the 

building. We note that all items brought 

to CMS, whether personal or for the 

purpose of demonstration or to support 

a demonstration, are subject to 

inspection. 

We cannot assume responsibility for 

coordinating the receipt, transfer, 

transport, storage, set-up, safety, or 

timely arrival of any personal 

belongings or items used for 

demonstration or to support a 

demonstration. 

Note: Individuals who are not registered in 

advance will not be permitted to enter the 

building and will be unable to attend the 

meeting. The public may not enter the 

building earlier than 90 minutes prior to the 

convening of the meeting. All visitors must 

be escorted in areas other than the lower and 

first floor levels in the Central Building. 

Seating capacity is limited to the first 350 

registrants. 

Authority: Section 3022 of the Affordable 

Care Act. 

Dated: September 13, 2010. 

By Direction of the Commission. 

Donald S. Clark, 

Secretary, The Federal Trade Commission. 

Dated: September 9, 2010. 

Donald M. Berwick, 

Administrator, Centers for Medicare & 

Medicaid Services. 

Dated: September 13, 2010. 

Daniel R. Levinson, 

Inspector General. 

[FR Doc. 2010–23340 Filed 9–16–10; 8:45 am] 

BILLING CODE 6750–01–P; 4120–01–P; 4152–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Musculoskeletal, Oral 

and Skin Sciences Integrated Review Group; 

Skeletal Muscle and Exercise Physiology 

Study Section. 

Date: October 12–13, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Richard Ingraham, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4116, 

MSC 7814, Bethesda, MD 20892, 301–496– 

8551, ingrahamrh@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Risk 

Prevention and Intervention Addictions: 

Overflow. 

Date: October 14–15, 2010. 

Time: 8 a.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Georgetown Suites, 1000 29th Street, 

NW., Washington, DC 20007. 

Contact Person: Gabriel B. Fosu, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

3562, fosug@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Pathogens and Symbiotes. 

Date: October 19–20, 2010. 

Time: 8:30 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Richard G Kostriken, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3192, 

MSC 7808, Bethesda, MD 20892, 301–402– 

4454, kostrikr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Mechanisms and Circuits Underlying 

Arousal. 

Date: October 19–20, 2010. 

Time: 9 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Kristin Kramer, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5205, 

MSC 7846, Bethesda, MD 20892, (301) 437– 

0911, kramerkm@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Toxicology. 

Date: October 19, 2010. 

Time: 11 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rass M. Shayiq, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Room 2182, 

MSC 7818, Bethesda, MD 20892, (301) 435– 

2359, shayiqr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR10–142: 

Interface of the Life and Physical Sciences. 

Date: October 20–22, 2010. 

Time: 8 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott Suites, 6711 

Democracy Boulevard, Bethesda, MD 20817. 

Contact Person: Malgorzata Klosek, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7849, Bethesda, MD 20892, (301) 435– 

2211, klosekm@csr.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Health Services Organization and Delivery 

Study Section. 

Date: October 20–21, 2010. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: InterContinental Mark Hopkins 

Hotel, 999 California Street, San Francisco, 

CA 94108. 

Contact Person: Kathy Salaita, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3172, 

MSC 7770, Bethesda, MD 20892, 301–451– 

8504, salaitak@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–08– 

062: Alzheimer’s Disease Pilot Clinical 

Trials. 

Date: October 22, 2010. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Estina E Thompson, PhD, 

MPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3178, 

MSC 7848, Bethesda, MD 20892, 301–496– 

5749, thompsone@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: Biomedical Technology Research 

Resource. 

Date: October 24–26, 2010. 

Time: 7 p.m. to 11 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Beacon Hill Hotel, 25 Charles Street, 

Boston, MA 02114. 

Contact Person: Lee Rosen, PhD, Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 5116, MSC 7854, Bethesda, MD 

20892, (301) 435–1171, rosenl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Cancer and 

Musculoskeletal Imaging Applications. 

Date: October 25, 2010. 

Time: 8 a.m. to 5 p.m. 


wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1